.png){kind=icon}
.png){kind=icon}
Return
PROTAC Technology: Opportunities and Challenges
.png){kind=icon}
OA
AI
DOI：10.1021/acsmedchemlett.9b00597.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
PROTACs-induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises (e.g., AstraZeneca, Bayer, Novartis, Amgen, Pfizer, GlaxoSmithKline, Merck, and Boehringer Ingelheim, etc.), and biotechnology companies. PROTACs opened a new chapter for novel drug development. However, any new technology will face many new problems and challenges. Perspectives on the potential opportunities and challenges of PROTACs will contribute to the research and development of new protein degradation drugs and degrader tools.
Keywords:
Proteolysis targeting chimeras
drug resistance
nonenzymatic function
undruggable target
reversible protein chemical knockdown
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
4
Papers:
4.4K
Citations:
10.0K